Inivata_CMYK_Logo.jpg
Inivata Announces RaDaR™ Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program
January 11, 2022 07:00 ET | Inivata
Inivata Announces RaDaR™ Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program Research Triangle Park, NC, USA and Cambridge, UK, 11 January 2022 -- Inivata, a leader...
Inivata_CMYK_Logo.jpg
Inivata Appoints David Eberhard MD, PhD as Chief Medical Officer
December 13, 2021 07:00 ET | Inivata
Inivata Appoints David Eberhard MD, PhD as Chief Medical Officer Research Triangle Park, NC, USA and Cambridge, UK, 13 December 2021 -- Inivata, a leader in liquid biopsy, today announced the...
Inivata_CMYK_Logo.jpg
Inivata Announces Clinical Collaboration with Princess Margaret Cancer Center for the use of its Liquid Biopsy Assays
October 19, 2021 07:00 ET | Inivata
Inivata Announces Clinical Collaboration with Princess Margaret Cancer Center for the use of its Liquid Biopsy Assays Two clinical studies including interventional RaDaR™ study Research Triangle...
Inivata_CMYK_Logo.jpg
Inivata and collaborators to present data that further validate the application of its RaDaR™ MRD and InVisionFirst®-Lung assays at the ESMO Congress 2021
September 09, 2021 07:00 ET | Inivata
Inivata and collaborators to present data that further validate the application of its RaDaR™ MRD and InVisionFirst®-Lung assays at the ESMO Congress 2021 Research Triangle Park, NC, USA and...
Inivata_CMYK_Logo.jpg
Inivata Announces Collaboration with F-star Therapeutics for the use of RaDaRTM Assay
May 25, 2021 07:00 ET | Inivata
Inivata Announces Collaboration with F-star Therapeutics for the use of RaDaRTM Assay RaDaR ctDNA liquid biopsy to monitor response of late-stage solid tumors to treatment Research Triangle Park,...
Inivata_CMYK_Logo.jpg
Inivata to be Acquired by NeoGenomics
May 05, 2021 07:00 ET | Inivata
Inivata to be Acquired by NeoGenomics Exercise of purchase option to acquire remaining Inivata equity interest for $390m Inivata to become a liquid biopsy focused division of NeoGenomics Research...
Inivata_CMYK_Logo.jpg
Inivata and Agendia Sign Agreement for Commercialization of RaDaR® MRD Liquid Biopsy Assay in Breast Cancer
April 28, 2021 07:00 ET | Inivata
Inivata and Agendia Sign Agreement for Commercialization of RaDaR® MRD Liquid Biopsy Assay in Breast Cancer Agendia granted co-exclusive distribution rights for RaDaR in North America and Europe ...
Inivata_CMYK_Logo.jpg
Inivata Presents New Data in Support of its Liquid Biopsy Technologies at AACR Virtual Annual Meeting 2021
April 10, 2021 08:30 ET | Inivata
Inivata Presents New Data in Support of its Liquid Biopsy Technologies at AACR Virtual Annual Meeting 2021 Inivata’s RaDaR® MRD assay performed with exceptionally high sensitivity and...
Inivata_CMYK_Logo.jpg
Inivata to Present New Data in Support of its RaDaR™ MRD and InVisionFirst®-Lung tests at AACR Virtual Annual Meeting 2021
March 17, 2021 08:00 ET | Inivata
Inivata to Present New Data in Support of its RaDaR™ MRD and InVisionFirst®-Lung tests at AACR Virtual Annual Meeting 2021 Research Triangle Park, NC, USA and Cambridge, UK, 17 March 2021 --...
Inivata_CMYK_Logo.jpg
FDA Grants Breakthrough Device Designation for Inivata’s RaDaR™ Assay
March 09, 2021 07:00 ET | Inivata
FDA Grants Breakthrough Device Designation for Inivata’s RaDaR™ Assay Designation will help accelerate the regulatory path of RaDaR for use in detection of MRD in early-stage cancer patients ...